PKI
Revvity, Inc. (formerly PerkinElmer; legacy PKI)
Is PKI Halal?
Diagnostics and life sciences tools with acceptable compliance.
What You Should Know
The legacy PKI route now represents Revvity (the issuer changed its common-stock ticker to RVTY in 2023). Revvity's April 5, 2026 Form 10-Q reports $11,996.590 million of assets, $3,207.903 million of interest-bearing debt, $860.320 million of cash, $691.380 million of receivables and $711.118 million of quarterly revenue. Debt/assets is 26.74%, liquidity/assets is 7.17%, receivables-plus-cash/assets is 12.93% and disclosed interest income is 0.89% of revenue; the examined FTSE, MSCI and Malaysia asset ratios pass, while market-cap methods remain uncalculated. The existing /assets/pki URL is retained for SEO continuity.
⚠️ Concerns
- •PKI is a legacy ticker; current common stock trades as RVTY
- •Clinical and research customer end uses
- •Interest-bearing debt
- •Interest income
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-04-05; calculated 2026-07-15.
3,207.903 / 11,996.59
860.32 / 11,996.59
1,551.7 / 11,996.59
6.304 / 711.118
- Financial
- Pass
- Overall
- Pass
Debt/assets is 26.74%, liquidity/assets is 7.17%, receivables-plus-cash/assets is 12.93% and disclosed interest income is 0.89% of revenue; examined FTSE ratios and core activity pass.
- Financial
- Pass
- Overall
- Pass
Debt/assets, liquidity/assets and receivables-plus-cash/assets are below the examined MSCI total-assets limits; this is not an index-membership claim.
- Financial
- Pass
- Overall
- Pass
Debt/assets and liquidity/assets are below the examined Malaysia limits; this is a calculation, not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A properly licensed historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
Revvity, the successor issuer to the legacy PKI route, provides life-sciences, diagnostics, imaging, informatics and research tools. The core activity is generally permissible.
Limitation: The filing does not classify every clinical, reproductive-health, research or software end use into a scholar-approved prohibited-revenue numerator.
Purification
Revvity discloses $6.304 million of interest income, but does not provide a scholar-approved purification percentage or separate prohibited-activity numerator.
Inputs, assumptions and primary sources
- Amounts are USD millions converted from Revvity's April 5, 2026 Form 10-Q values reported in thousands.
- The route retains legacy ticker PKI for URL stability; the issuer changed its common-stock ticker to RVTY in May 2023, so this record uses the current successor filing rather than presenting PKI as an active quote.
- Interest-bearing debt includes $575.831 million of current debt and $2,632.072 million of long-term debt; operating lease liabilities are excluded.
- Cash is $860.320 million. No separately identifiable interest-bearing securities are reported in the selected balance-sheet captions, so the proxy is zero.
- Accounts receivable are $691.380 million net; quarterly revenue is $711.118 million and disclosed interest income is $6.304 million.
- Revvity's life-sciences, diagnostics and research tools are generally permissible, while customer end uses require qualitative review.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →